Hidoc Dr | Medical Learning App for Doctors

Today's Updates

CHEST 2026 Preview: Late-Breakers to Watch Out For

Published Date: 16 Oct 2026

CHEST 2026 Preview: Late-Breakers to Watch Out For

Clinical Forum Insights: When to Escalate to Biologics in Asthma and COPD?

Published Date: 16 Oct 2026

Clinical Forum Insights: When to Escalate to Biologics in Asthma and COPD?

ELEVIDYS Shows Sustained Functional Differences vs External Controls in Older Ambulatory Duchenne Patients Louie Pasculli

Published Date: 16 Oct 2026

New analyses found differences in functional outcomes over 2 years among patients aged 8 to 12 years treated with delandistrogene moxeparvovec, while separate findings characterized micro-dystrophin expression in children younger than 3 years.

Dompé Begins Phase 2 Trial Testing Intranasal Nerve Growth Factor for Cerebral Palsy Marco Meglio

Published Date: 16 Oct 2026

The Galassia trial will evaluate the safety and tolerability of intranasal cenegermin in about 60 children with spastic cerebral palsy across Italy.

Telitacicept Shows Deepening, Durable Response in Myasthenia Gravis Marco Meglio

Published Date: 16 Oct 2026

New 48-week phase 3 data show many patients with generalized myasthenia gravis reached minimal symptom expression on telitacicept, and most who did sustained it.

NeuroVoices: Ali Habib, MD, on Cemdisiran and the Phase 3 NIMBLE Trial Data in Myasthenia Gravis Marco Meglio, Ali Habib, MD

Published Date: 16 Oct 2026

The professor of neurology and program director of Neuromuscular Medicine at UC Irvine, discusses phase 3 NIMBLE trial findings for cemdisiran in generalized myasthenia gravis, including its novel siRNA mechanism, efficacy, and hospitalization data.

Arimoclomol Plus Miglustat Shows Early, Sustained Slowing of Niemann-Pick Disease Type C Progression Isabella Ciccone, MPH

Published Date: 16 Oct 2026

A post hoc analysis of the phase 2/3 NPC002 trial presented at CNS 2026 showed that the benefit of arimoclomol plus miglustat in Niemann-Pick disease type C emerged as early as 3 months after treatment initiation.

Fenfluramine Shows Consistent Seizure Reduction Across Age Groups in CDKL5 Deficiency Disorder Isabella Ciccone, MPH

Published Date: 16 Oct 2026

An analysis of the phase 3 GEMZ trial presented at CNS 2026 showed that fenfluramine produced comparable seizure reductions and safety outcomes in children and adults with CDKL5 deficiency disorder.

Antifungal Therapy Eased IBD Activity, With Iliyan D. Iliev, PhD Iliyan D. Iliev, PhD

Published Date: 16 Oct 2026

Fluconazole was linked to improved Mayo and Harvey-Bradshaw scores; Iliev outlines the placebo-controlled trial needed next.

Dupilumab Improves Esophageal Distensibility in EoE: REMODEL Trial Evan Dellon, MD, MPH

Published Date: 16 Oct 2026

Evan Dellon, MD, MPH, discusses REMODEL data showing dupilumab widened the esophagus vs placebo, with the biggest gains in patients with narrower caliber.

Knowledge Hub

Oncology

Screening for Treatment-Related Sarcopenia in Cancer Care

Comprehensive review on screening for treatment-related sarcopenia in cancer patients, with clinical insights and guideline-based recommendations.

Oncology

Tissue Reconstruction After Extensive Cancer Surgery: Advances, Challenges, and Clinical Considerations

Comprehensive review of tissue reconstruction strategies following extensive cancer surgery for healthcare professionals.

Oncology

Therapeutic RNA Vaccines for Melanoma

Comprehensive review of therapeutic RNA vaccines and their clinical relevance in melanoma management.

Oncology

Cancer Staging Education Through Interactive Anatomical Spread Maps

Review of interactive anatomical spread maps as innovative tools for cancer staging education in clinical practice.

Oncology

KOL Videos

Hidoc Dr| Hidoc- US| Hidoc - Doctor Netwoking Platform| Educational resource for HCPs

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

Your one-stop Solution for MEDICAL LEARNING & UPDATES

CHEST 2026 Preview: Late-Breakers to Watch Out For

Clinical Forum Insights: When to Escalate to Biologics in Asthma and COPD?

ELEVIDYS Shows Sustained Functional Differences vs External Controls in Older Ambulatory Duchenne Patients Louie Pasculli

Dompé Begins Phase 2 Trial Testing Intranasal Nerve Growth Factor for Cerebral Palsy Marco Meglio

Telitacicept Shows Deepening, Durable Response in Myasthenia Gravis Marco Meglio

NeuroVoices: Ali Habib, MD, on Cemdisiran and the Phase 3 NIMBLE Trial Data in Myasthenia Gravis Marco Meglio, Ali Habib, MD

Arimoclomol Plus Miglustat Shows Early, Sustained Slowing of Niemann-Pick Disease Type C Progression Isabella Ciccone, MPH

Fenfluramine Shows Consistent Seizure Reduction Across Age Groups in CDKL5 Deficiency Disorder Isabella Ciccone, MPH

Antifungal Therapy Eased IBD Activity, With Iliyan D. Iliev, PhD Iliyan D. Iliev, PhD

Dupilumab Improves Esophageal Distensibility in EoE: REMODEL Trial Evan Dellon, MD, MPH

Knowledge Hub

Screening for Treatment-Related Sarcopenia in Cancer Care

Tissue Reconstruction After Extensive Cancer Surgery: Advances, Challenges, and Clinical Considerations

Therapeutic RNA Vaccines for Melanoma

Cancer Staging Education Through Interactive Anatomical Spread Maps

Reconstruction of Surgical Defects After Cancer Resection

Reproductive Hormones and Immune Cell Metabolism: Mechanisms, Clinical Implications, and Emerging Evidence

Physical Recovery During Cancer Survivorship: Clinical Perspectives and Evidence-Based Approaches

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Page Views

Your one-stop Solution for MEDICAL LEARNING & UPDATES

CHEST 2026 Preview: Late-Breakers to Watch Out For

Clinical Forum Insights: When to Escalate to Biologics in Asthma and COPD?

ELEVIDYS Shows Sustained Functional Differences vs External Controls in Older Ambulatory Duchenne Patients Louie Pasculli

Dompé Begins Phase 2 Trial Testing Intranasal Nerve Growth Factor for Cerebral Palsy Marco Meglio

Telitacicept Shows Deepening, Durable Response in Myasthenia Gravis Marco Meglio

NeuroVoices: Ali Habib, MD, on Cemdisiran and the Phase 3 NIMBLE Trial Data in Myasthenia Gravis Marco Meglio, Ali Habib, MD

Arimoclomol Plus Miglustat Shows Early, Sustained Slowing of Niemann-Pick Disease Type C Progression Isabella Ciccone, MPH

Fenfluramine Shows Consistent Seizure Reduction Across Age Groups in CDKL5 Deficiency Disorder Isabella Ciccone, MPH

Antifungal Therapy Eased IBD Activity, With Iliyan D. Iliev, PhD Iliyan D. Iliev, PhD

Dupilumab Improves Esophageal Distensibility in EoE: REMODEL Trial Evan Dellon, MD, MPH

Knowledge Hub

Screening for Treatment-Related Sarcopenia in Cancer Care

Tissue Reconstruction After Extensive Cancer Surgery: Advances, Challenges, and Clinical Considerations

Therapeutic RNA Vaccines for Melanoma

Cancer Staging Education Through Interactive Anatomical Spread Maps

Reconstruction of Surgical Defects After Cancer Resection

Reproductive Hormones and Immune Cell Metabolism: Mechanisms, Clinical Implications, and Emerging Evidence

Physical Recovery During Cancer Survivorship: Clinical Perspectives and Evidence-Based Approaches

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Verification

Welcome to Hidoc Dr.

Page Views